Literature DB >> 8396359

Recurrence of hepatocellular carcinoma in the liver remnant after hepatic resection.

K Ouchi1, S Matsubara, K Fukuhara, T Tominaga, S Matsuno.   

Abstract

We analyzed the results of 19 patients who had intrahepatic recurrence of hepatocellular carcinoma (HCC) among 47 patients who were discharged from the hospital after having a hepatic resection in order to evaluate the factors affecting recurrence and survival. Recurrence-free survival rates were 80%, 44%, and 28% at 1, 3, and 5 years, respectively. Of the 19 patients with recurrence, 14 had multiple lesions, and 16 of the recurrences were detected within 3 years of surgery. None of the following factors correlated with recurrence: hepatic function; tumor size; presence of tumor capsule; capsular invasion; vascular invasion and intrahepatic metastasis; extent of hepatic resection; and resection with tumor-free margins. Patients having multiple recurrent HCCs, however, had larger-sized tumors at the time of resection than those with a solitary recurrence. The survival rates after recurrence were significantly better in patients with a solitary recurrence, and these patients were treated with transcatheter arterial embolization (TAE) therapy. Early detection as well as TAE for recurrent HCCs is necessary to improve long-term survival.

Entities:  

Mesh:

Year:  1993        PMID: 8396359     DOI: 10.1016/s0002-9610(05)80972-9

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  10 in total

1.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

2.  Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal.

Authors:  R T Poon; S T Fan; I O Ng; J Wong
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

Review 3.  Therapeutic modalities and prognostic factors for primary and secondary liver tumors.

Authors:  T Lehnert; G Otto; C Herfarth
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

4.  Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years.

Authors:  R T Poon; S T Fan; C M Lo; I O Ng; C L Liu; C M Lam; J Wong
Journal:  Ann Surg       Date:  2001-07       Impact factor: 12.969

5.  Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma.

Authors:  M Shimada; K Takenaka; K Taguchi; Y Fujiwara; T Gion; K Kajiyama; T Maeda; K Shirabe; K Yanaga; K Sugimachi
Journal:  Ann Surg       Date:  1998-01       Impact factor: 12.969

Review 6.  Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; Flora Hau-Fung Tsang; John Wong
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

7.  Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis.

Authors:  S Ko; Y Nakajima; H Kanehiro; M Hisanaga; Y Aomatsu; T Kin; K Yagura; T Ohyama; K Nishio; K Ohashi; M Sho; T Yamada; H Nakano
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

Review 8.  Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma.

Authors:  R Tung-Ping Poon; S T Fan; J Wong
Journal:  Ann Surg       Date:  2000-07       Impact factor: 12.969

9.  Early recurring hepatocellular carcinoma after partial hepatic resection: preoperative CT findings.

Authors:  J H Lim; H J Jang; E Y Kim; C K Park; J W Joh; Y I Kim
Journal:  Korean J Radiol       Date:  2000 Jan-Mar       Impact factor: 3.500

10.  The utility of gadoxetic acid-enhanced magnetic resonance imaging in the surveillance for postoperative recurrence of hepatocellular carcinoma.

Authors:  Jung Hee Kim; Yang Won Min; Geum-Youn Gwak; Yong Han Paik; Moon Seok Choi; Joon Hyoek Lee; Kwang Cheol Koh; Seung Woon Paik
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.